Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects

European Journal of Epidemiology

Volumn 17, Issue 2, 2001, Pages 135-140

  Gasparini, R ^a   Pozzi, T ^a   Montomoli, E ^a   Fragapane, E ^a   Senatore, F ^b   Minutello, M ^b   Podda, A ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b CHIRON VACCINES   (Italy)

Author keywords

Adjuvant; Influenza; Randomised control trials; Vaccine

Indexed keywords

INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; FEMALE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA VACCINATION; INJECTION PAIN; INJECTION SITE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; AGED; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; ITALY; MALE; POLYSORBATES; PROSPECTIVE STUDIES; SQUALENE; TIME FACTORS; VACCINES, SUBUNIT;

EID: 0034801645     PISSN: 03932990     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1017919305501     Document Type: Article

References (43)

1. Influenza vaccination of elderly persons: Reduction in pneumonia and influenza hospitalizations and deaths
2. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970-78
3. Impact of epidemics upon communities and families
4. Risk factors for Influenza mortality?
5. Health impact of influenza in the United States
6. A study of excess mortality during influenza epidemics in the United States, 1968-1976
7. An outbreak of influenza B in an elderly population
8. Preventing influenza and its complications: A public health initiative for the year 2000
9. Reduction in mortality associated with influenza vaccine during 1989-90 epidemic
10. Influenza vaccination for all elderly
11. Efficacy and adverse reactions of influenza vaccine in the elderly
12. Effectiveness of influenza vaccine in the elderly
13. Influenza vaccination programs for elderly persons: Cost-effectiveness in a health maintenance organization
14. Clinical effectiveness of influenza vaccination in Manitoba
15. Immunogenicity of an inactivated split influenza vaccine in institutionalized elderly patients
16. Efficacy of Influenza vaccine in nursing homes: Reduction in illness and complications during an influenza A(H3N2) epidemic
17. Influenza in the elderly: Report of an outbreak and a review of vaccine effectiveness reports
18. Alternatives in the control of influenza
19. Influenza vaccination in subjects of the local health unit Arezzo (Tuscany-Italy) during the winter 1990/91
20. Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents
21. The clinical efficacy of influenza vaccination
22. Dose-comparative serological studies: Critical evaluation of the parameters to assess the antibody response to Influenza vaccination
23. Nasal Cholera Toxin-B combined Influenza Vaccine
24. Evaluation of heat labile enterotoxin (LT) from Escherichia coli as an adjuvant for oral immunization with inactivated Influenza virus vaccine
25. Development of a new type of influenza subunit vaccine made by muramyldipeptide-liposome: Enhancement of humoral and cellular immune responses
26. "Liposomal vaccines and mucosal immunity"
27. Adjuvant effect of low-dose interleukin-2 on antibody response to influenza virus vaccination in healthy elderly subjects
28. Vaccine-related determinants of the interleukin-2 response to influenza vaccination in healthy young and elderly adults
29. Augmentation of the immune response to influenza vaccine by acetylsalicylic acid: A clinical trial in a geriatric population
30. Humoral response to influenza hemagglutinin: Oligoclonal spectrotype and failure of thymopentin as immunoadjuvant
31. The effect of DHEAS on influenza vaccination in ageing adults
32. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines
33. Adjuvants for human vaccines-current status, problems and future prospects
34. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice
35. Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly
36. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons
37. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly
38. Influenza vaccines: Antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population
39. Recommended composition of influenza virus vaccines for use in the 1994-1995 season
40. Influenza viruses
41. Influenza mortality among the elderly in France, 1980-90: How many deaths may have been avoided through vaccination?